Tag
This phase II study evaluates pembrolizumab combined with carboplatin/paclitaxel and HIPEC in neoadjuvant therapy, followed by pembrolizumab maintenance with or without olaparib in advanced stage III/IV epithelial ovarian cancer patients.
Laparoscopic HIPEC following upfront treatment in advanced epithelial ovarian cancer is feasible, safe, and preserves patient quality of life, offering a promising consolidation approach.
A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias,
22-year single-center data confirm CRS and HIPEC as safe, effective for PMP, yielding 62% 5-year survival. Prognostic factors, optimized HIPEC regimens, and perioperative management impact outcomes and recurrence.
A randomized trial found that maintaining high intraoperative urine output (≥3 ml·kg−1·h−1 or ≥200 ml·h−1) during cytoreductive surgery and cisplatin‑based HIPEC reduced 7‑day postoperative AKI from 39.3% to 21.4% and lowered major 30‑day c
